Long-term management of chronic immune thrombocytopenic purpura in adults

International Journal of General Medicine

Volumn 3, Issue , 2010, Pages 305-311

  Palau, Javier ^a   Jarque, Isidro ^a   Sanz, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Corticosteroids; Eltrombopag; Rituximab; Romiplostim; Splenectomy

Indexed keywords

AMINOCAPROIC ACID; ASCORBIC ACID; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; DAPSONE; DEXAMETHASONE; ELTROMBOPAG; ETOPOSIDE; GLUCOCORTICOID; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INTERFERON; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT THROMBOPOIETIN; RETICULIN; RHESUS D ANTIBODY; RITUXIMAB; ROMIPLOSTIM; STEROID; TRANEXAMIC ACID; UNINDEXED DRUG; VINCRISTINE;

ADULT; ADVERSE OUTCOME; ARTICLE; BACTERIAL INFECTION; BLEEDING; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CYTOMEGALOVIRUS; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG TREATMENT FAILURE; EPSTEIN BARR VIRUS; FOLLOW UP; HELICOBACTER PYLORI; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOADSORPTION; INFECTION; KIDNEY FAILURE; LIVER DYSFUNCTION; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; PARVOVIRUS; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROPHYLAXIS; PROTEIN BLOOD LEVEL; REMISSION; RISK FACTOR; SIDE EFFECT; SPLENECTOMY; THERAPY EFFECT; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR; VACCINATION; VAGINA BLEEDING; VIRUS INFECTION;

EID: 80052451570     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386-2393.
2. Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9:1123-1124.
3. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102:887-895.
4. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103:1364-1369.
5. Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103:500-506.
6. Zhang F, Chu X, Wang L, et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2006;76:427-431.
7. Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med. 1995;98:436-442.
8. Kuhne T, Imbach P, Bolton-Maggs PH, et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001;358:2122-2125.
9. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4:2377-2383.
10. Blanchette VS, Luke B, Andrew M, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr. 1993;123:989-995.
11. Lilleyman JS. Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol. 1999;105:871-875.
12. Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Eng J Med. 2003;349:831-836.
13. Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122:966-974.
14. Stasi R, Evangelista ML, Stipa E, et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008;99:4-13.
15. Cortelazzo S, Finazzi G, Buelli M, et al. High-risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood. 1991;77:31-33.
16. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97:2549-2554.
17. Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost. 1977;3:160-174.
18. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood. 2005;106:2244-2251.
19. Guthrie TH, Brannan DP, Prisant LM. Idiopathic thrombocytopenic purpura in the older adult patient. Am J Med Sci. 1988;296:17-21.
20. Carr JM, Kruskall MS, Kaye JA, et al. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med. 1986;80:1051-1054.
21. Baumann MA, Menitove JE, Aster RH, Anderson T. Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gamma globulin infusion followed by platelet transfusion. Ann Intern Med. 1986;104:808-809.
22. Spahr JE, Rodgers GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol. 2008; 83:122-125.
23. Gerotziafas GT, Zervas C, Gavrielidis G, et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol. 2002;69:219-222.
24. Culic S. Recombinant factor VIIa for refractive hemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol. 2003;120:909-910.
25. Waddington DP, McAuley FT, Hanley JP, Summerfield GP. The use of recombinant factor VIIa in a Jehovah's witness with autoimmune thrombocytopenia and post-splenectomy hemorrhage. Br J Haematol. 2002;119:286-288.
26. Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009;46(1 Suppl 2):S2-S14.
27. Stasi R. Therapeutic strategies for hepatitis and other infection-related immune thrombocytopenias. Semin Hematol. 2009;46(1 Suppl 2): S15-S25.
28. DiMaggio D, Anderson A, Bussel JB. Cytomegalovirus can make immune thrombocytopenic purpura refractory. Br J Haematol. 2009; 146:104-112.
29. Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G. Highdose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol. 2004; 83:764-768.
30. Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura. A GIMEMA experience. Blood. 2007;109:1401-1407.
31. George JN, Vesely SK. Immune thrombocytopenic purpura let the treatment fit the patient. N Engl J Med. 2003;349:903-905.
32. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104:2623-2634.
33. Fabris F, Tassan T, Ramon R, et al. Age as the major predictive factor of long-term response to splenectomy in immune thrombocytopenic purpura. Br J Haematol. 2001;112:637-640.
34. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004;104:956-960.
35. Kumar S, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. Ann Hematol. 2002;81:312-319.
36. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3-40.
37. Fenaux P, Caulier MT, Hirschauer MC, Beuscart R, Goudemand J, Bauters F. Reevaluation of the prognostic factors for splenectomy in chronic idiopathic thrombocytopenic purpura (ITP): a report on 181 cases. Eur J Haematol. 1989;42:259-264.
38. Katkhouda N, Mavor E. Laparoscopic splenectomy. Surg Clin North Am. 2000;80:1285-1297.
39. Tanoue K, Okita K, Akahoshi T, et al. Laparoscopic splenectomy for hematologic diseases. Surgery. 2002;131 Suppl 1:S318-S323.
40. Wu JM, Lai IR, Yuan RH, Yu SC. Laparoscopic splenectomy for idiopathic thrombocytopenic purpura. Am J Surg. 2004;187:720-723.
41. Dolan JP, Sheppard BC, DeLoughery TG. Splenectomy for immune thrombocytopenic purpura: surgery for the 21st century. Am J Hematol. 2008;83:93-96.
42. Schilling RF. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med. 1995;122:187-188.
43. Stasi R, Brunetti M, Pagano A, Stipa E, Masi M, Amadori S. Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis. 2000;26:582-586.
44. Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med. 2004; 10:112-120.
45. Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol. 2004;83:764-768.
46. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-787.
47. Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997;89:2689-2700.
48. Quiquandon I, Fenaux P, Caulier MT, et al. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol. 1990;74:223-228.
49. Emilia G, Morselli M, Luppi M, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood. 2002;99:1482-1485.
50. Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol. 2001;114:121-125.
51. Verlin M, Laros RK Jr, Penner JA. Treatment of refractory thrombocytopenic purpura with cyclophosphamide. Am J Hematol. 1976;1: 97-104.
52. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995; 85:351-358.
53. Maloisel F, Andres E, Zimmer J, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med. 2004;116:590-594.
54. Vancine-Califani SM, De Paula EV, Ozelo MC, et al. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. Platelets. 2008;19:489-495.
55. Hernandez F, Linares M, Colomina P, et al. Dapsone for refractory chronic idiopathic thrombocytopenic purpura. Br J Haematol. 1995; 90:473-475.
56. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol. 2006;81:19-25.
57. Kotb R, Pinganaud C, Trichet C, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol. 2005;75:60-64.
58. Arnold DM, Nazi I, Santos A, et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood. 2010;115:29-31.
59. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25-33.
60. Godeau B, Porcher R, Fain O, Lefrere F, Fenaux P, Cheze S. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112:999-1004
61. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010; 115(14):2755-2762.
62. Carson KR, Evens AM, Richey AE, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834-4840.
63. Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer. 2006;107:136-140.
64. Berchtold P, McMillan R. Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood. 1989;74:2309-2317.
65. Szczepanik AB, Sikorska A, Slomkowski M, Konopka L. The use of vinca alkaloids in preparation for splenectomy of corticosteroid refractory chronic immune thrombocytopenic purpura patients. Int J Lab Hematol. 2007;29:347-351.
66. Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood. 2007;110:3526-3531.
67. Figueroa M, Gehlsen J, Hammond D, et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med. 1993; 328:1226-1229.
68. McMillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. N Engl J Med. 2001;344:1402-1403.
69. Zaydan MA, Turner C, Miller AM. Resolution of chronic idiopathic thrombocytopenia purpura following syngeneic peripheral blood progenitor transplant. Bone Marrow Transplant. 2002;29:87-89.
70. Butler JP, Durrant ST, Frost T. Successful remission of chronic, refractory autoimmune thrombocytopenic purpura following non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2003;31:621-622.
71. Huhn RD, Fogarty PF, Nakamura R. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood. 2003;101:71-77.
72. Passweg JR, Rabusin M. Hematopoietic stem cell transplantation for immune thrombocytopenia and other refractory autoimmune cytopenias. Autoimmunity. 2008;41:660-665.
73. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2004;25:52-60
74. Newland A, Caulier MT, Kappers-Klunne M, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol. 2006;135:547-553.
75. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesisstimulating protein, for chronic ITP. N Engl J Med. 2006;355: 1672-1681.
76. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a doubleblind randomised controlled trial. Lancet. 2008;371:395-403.
77. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113:2161-2171.
78. George JN, Mathias SD, Go RS, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol. 2009;144:409-415.
79. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237-2247.
80. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:641-648.
81. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168-186.